cbdMD Inc
NYSE MKT: YCBD · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-04-30
cbdMD Inc (YCBD) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for YCBD.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
YCBD historical valuation range
Where current P/E sits in YCBD's own 5Y range.
YCBD intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
YCBD valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 1.62x
P/S Ratio — History
Current: 0.53x
Is YCBD overvalued in 2026?
cbdMD Inc (YCBD) currently trades at $0.85 per share with a market capitalization of $10,180,700.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 28/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 1.6x.
Our discounted cash flow model estimates YCBD's intrinsic value at $3.16 per share, against the current market price of $0.85. This implies a margin of safety of +76.15%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: YCBD appears richly valued on our framework, with a Smart Value Score of 28/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is YCBD overvalued in 2026?
Based on a Smart Value Score of 28/100, YCBD appears overvalued. Current price exceeds what fundamentals currently justify.
What is YCBD's fair value?
Our DCF model estimates YCBD's intrinsic value at $3.16 per share, versus the current price of $0.85. This produces a margin of safety of +76.15%.
What P/E ratio does YCBD trade at?
YCBD trades at a P/E of 1.6x on trailing twelve-month earnings.
Is YCBD a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 28/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does YCBD's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on YCBD.
What is YCBD's Smart Value Score?
YCBD's Smart Value Score is 28/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.